These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 22847255)

  • 1. Screening of budesonide nanoformulations for treatment of inflammatory bowel disease in an inflamed 3D cell-culture model.
    Leonard F; Ali H; Collnot EM; Crielaard BJ; Lammers T; Storm G; Lehr CM
    ALTEX; 2012; 29(3):275-85. PubMed ID: 22847255
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design and in vitro characterization of multistage silicon-PLGA budesonide particles for inflammatory bowel disease.
    Leonard F; Srinivasan S; Liu X; Collnot EM; Ferrari M; Lehr CM; Godin B
    Eur J Pharm Biopharm; 2020 Jun; 151():61-72. PubMed ID: 32283213
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Budesonide Loaded PLGA Nanoparticles for Targeting the Inflamed Intestinal Mucosa--Pharmaceutical Characterization and Fluorescence Imaging.
    Ali H; Weigmann B; Collnot EM; Khan SA; Windbergs M; Lehr CM
    Pharm Res; 2016 May; 33(5):1085-92. PubMed ID: 26718953
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Budesonide loaded nanoparticles with pH-sensitive coating for improved mucosal targeting in mouse models of inflammatory bowel diseases.
    Ali H; Weigmann B; Neurath MF; Collnot EM; Windbergs M; Lehr CM
    J Control Release; 2014 Jun; 183():167-77. PubMed ID: 24685705
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A three-dimensional coculture of enterocytes, monocytes and dendritic cells to model inflamed intestinal mucosa in vitro.
    Leonard F; Collnot EM; Lehr CM
    Mol Pharm; 2010 Dec; 7(6):2103-19. PubMed ID: 20809575
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Self assembled hyaluronic acid nanoparticles as a potential carrier for targeting the inflamed intestinal mucosa.
    Vafaei SY; Esmaeili M; Amini M; Atyabi F; Ostad SN; Dinarvand R
    Carbohydr Polym; 2016 Jun; 144():371-81. PubMed ID: 27083829
    [TBL] [Abstract][Full Text] [Related]  

  • 7. pH-sensitive nanoparticles for colonic delivery of curcumin in inflammatory bowel disease.
    Beloqui A; Coco R; Memvanga PB; Ucakar B; des Rieux A; Préat V
    Int J Pharm; 2014 Oct; 473(1-2):203-12. PubMed ID: 25014369
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-inflammatory effects of budesonide in intestinal epithelial cells.
    Fredin MF; Ulfhammer E; Rhedin M; Melgar S; Mellgård B; Peterson A
    Pharmacol Res; 2005 Nov; 52(5):422-8. PubMed ID: 16118056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug delivery to inflamed colon by nanoparticles: comparison of different strategies.
    Coco R; Plapied L; Pourcelle V; Jérôme C; Brayden DJ; Schneider YJ; Préat V
    Int J Pharm; 2013 Jan; 440(1):3-12. PubMed ID: 22820482
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PEG-functionalized microparticles selectively target inflamed mucosa in inflammatory bowel disease.
    Lautenschläger C; Schmidt C; Lehr CM; Fischer D; Stallmach A
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):578-86. PubMed ID: 24084650
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Co-spray dried resveratrol and budesonide inhalation formulation for reducing inflammation and oxidative stress in rat alveolar macrophages.
    Trotta V; Lee WH; Loo CY; Young PM; Traini D; Scalia S
    Eur J Pharm Sci; 2016 Apr; 86():20-8. PubMed ID: 26944422
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted delivery of Cyclosporine A by polymeric nanocarriers improves the therapy of inflammatory bowel disease in a relevant mouse model.
    Melero A; Draheim C; Hansen S; Giner E; Carreras JJ; Talens-Visconti R; Garrigues TM; Peris JE; Recio MC; Giner R; Lehr CM
    Eur J Pharm Biopharm; 2017 Oct; 119():361-371. PubMed ID: 28709903
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Redox-sensitive nanoparticles based on 4-aminothiophenol-carboxymethyl inulin conjugate for budesonide delivery in inflammatory bowel diseases.
    Sun Q; Luan L; Arif M; Li J; Dong QJ; Gao Y; Chi Z; Liu CG
    Carbohydr Polym; 2018 Jun; 189():352-359. PubMed ID: 29580419
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A self-assembled, ROS-responsive Janus-prodrug for targeted therapy of inflammatory bowel disease.
    Li S; Xie A; Li H; Zou X; Zhang Q
    J Control Release; 2019 Dec; 316():66-78. PubMed ID: 31682913
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparative study of curcumin-loaded lipid-based nanocarriers in the treatment of inflammatory bowel disease.
    Beloqui A; Memvanga PB; Coco R; Reimondez-Troitiño S; Alhouayek M; Muccioli GG; Alonso MJ; Csaba N; de la Fuente M; Préat V
    Colloids Surf B Biointerfaces; 2016 Jul; 143():327-335. PubMed ID: 27022873
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Budesonide-loaded nanostructured lipid carriers reduce inflammation in murine DSS-induced colitis.
    Beloqui A; Coco R; Alhouayek M; Solinís MÁ; Rodríguez-Gascón A; Muccioli GG; Préat V
    Int J Pharm; 2013 Oct; 454(2):775-83. PubMed ID: 23694806
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted delivery nano/micro particles to inflamed intestinal mucosa in human.
    Park K
    J Control Release; 2013 Jan; 165(2):162. PubMed ID: 23265297
    [No Abstract]   [Full Text] [Related]  

  • 18. Intestinal anti-inflammatory activity of luteolin: role of the aglycone in NF-κB inactivation in macrophages co-cultured with intestinal epithelial cells.
    Nishitani Y; Yamamoto K; Yoshida M; Azuma T; Kanazawa K; Hashimoto T; Mizuno M
    Biofactors; 2013; 39(5):522-33. PubMed ID: 23460110
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral liposomal delivery of an activatable budesonide prodrug reduces colitis in experimental mice.
    Xian S; Zhu J; Wang Y; Song H; Wang H
    Drug Deliv; 2023 Dec; 30(1):2183821. PubMed ID: 36861451
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A 3D co-culture of three human cell lines to model the inflamed intestinal mucosa for safety testing of nanomaterials.
    Susewind J; de Souza Carvalho-Wodarz C; Repnik U; Collnot EM; Schneider-Daum N; Griffiths GW; Lehr CM
    Nanotoxicology; 2016; 10(1):53-62. PubMed ID: 25738417
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.